The Relationship Between Primary Tumor Localization and Driver Mutation in Lung Cancer
Objectives: Driver mutations are detected in 30–35% of metastatic patients with non-small cell lung cancer (NSCLC), and mutation discordance may occur between biopsies. Therefore, false-negative results for a driver mutation are reported in some patients who may need re-biopsy. We aim to identify a clinicopathological feature (especially tumor localization), other than smoking and sex, that predicts driver mutation in metastatic non-squamous NSCLC.
Methods: A total of 75 patients with driver mutation reports were included in the study. The age, gender, smoking status, pathology, primary tumor location, and mutation of each patient were evaluated. The relationship between the clinicopathological features and driver mutations was analyzed.
Results: The median age of the patients was 66 (range: 36–85); 55 (73%) of the patients were male. A driver mutation was detected in 23 (30.7%) patients. EGFR, ALK, and ROS1 rates were 22.7%, 6.7%, and 1.3%, respectively. Driver mutations were mostly found found in females and non-smokers (the p-values were 0.029 and <0.001, respectively). Driver mutation rates were similar in the right and left lungs (p=0.504).
Conclusion: There was no relationship between primary tumor localization and driver mutations. Driver mutations were more common in females and in non-smoking patients.
1.Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394−424.
2. Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ Jr, Wu YL, et al. Lung cancer: current therapies and new targeted treatments. Lancet 2017;389:299−311.
3. Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 2015;16:141−51.
4. Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014;371:2167−77.
5. Kilickap S, Onder S, Dizdar O, Erman M, Uner A. Short-time use of crizotinib as neoadjuvant in ALK-positive non-small cell lung carcinoma can be a chance for resectability. Cancer Che-mother Pharmacol 2019;83:1195−96.
6. Ha SY, Choi S-J, Cho JH, Choi HJ, Lee J, Jung K, et al. Lung cancer in never-smoker Asian females is driven by oncogenic mutations, most often involving EGFR. Oncotarget 2015;6:5465.
7. Rodig SJ, Mino-Kenudson M, Dacic S, Yeap BY, Shaw A, Barletta JA, et al. Unique clinicopathologic features characterize ALKrearranged lung adenocarcinoma in the western population. Clin Cancer Res 2009;15:5216−23.
8. Mlika M, Dziri C, Zorgati MM, Ben Khelil M, Mezni F. Liquid Biopsy as Surrogate to Tissue in Lung Cancer for Molecular Profiling: A Meta-Analysis. Curr Respir Med Rev 2018;14:48−60.
9. Fatima N, Zaman MU, Maqbool A, Khan SH, Riaz N. Lower incidence but more aggressive behavior of right sided breast cancer in Pakistani women: does right deserve more respect? Asian Pac J Cancer Prev 2013;14:43−5.
10. Missiaglia E, Jacobs B, D'Ario G, Di Narzo AF, Soneson C, Budinska E, et al. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann Oncol 2014;25:1995−2001.
11. Roychoudhuri R, Putcha V, Møller H. Cancer and laterality: a study of the five major paired organs (UK). Cancer Causes Control 2006;17:655−62.
12. San Roman AK, Shivdasani RA. Boundaries, junctions and transitions in the gastrointestinal tract. Exp Cell Res 2011;317:2711−8.
13. Tie J, Gibbs P, Lipton L, Christie M, Jorissen RN, Burgess AW, et al. Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation. Int J Cancer 2011;128:2075−84.
14. Salem ME, Weinberg BA, Xiu J, El-Deiry WS, Hwang JJ, Gatalica Z, et al. Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers. Oncotarget 2017;8:86356−68.
15. Kuhnigk J-M, Hahn H, Hindennach M, Dicken V, Krass S, Peitgen H-O, editors. Lung lobe segmentation by anatomy-guided 3D watershed transform. Medical Imaging 2003. International Society for Optics and Photonics, 2003.
16. Berrocal T, Madrid C, Novo S, Gutiérrez J, Arjonilla A, GómezLeón N. Congenital anomalies of the tracheobronchial tree, lung, and mediastinum: embryology, radiology, and pathology. Radiographics 2004;24:e17.
17. Kawaguchi T, Takada M, Kubo A, Matsumura A, Fukai S, Tamura A, et al. Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC. J Thorac Oncol 2010;5:620−30.
18. Hsu LH, Chu NM, Liu CC, Tsai SY, You DL, Ko JS, et al. Sex-associated differences in non-small cell lung cancer in the new era: is gender an independent prognostic factor? Lung Cancer 2009;66:262−7.
19. Motoi N, Szoke J, Riely GJ, Seshan VE, Kris MG, Rusch VW, et al. Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol 2008;32:810−27.
20. Zhang YL, Yuan JQ, Wang KF, Fu XH, Han XR, Threapleton D, et al. The prevalence of EGFR mutation in patients with nonsmall cell lung cancer: a systematic review and meta-analysis. Oncotarget 2016;7:78985−93.
21. Ye M, Zhang X, Li N, Zhang Y, Jing P, Chang N, et al. ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance. Oncotarget 2016;7:12289−304.